title: B-cell chronic lymphocytic leukaemia: prognostic value of the immunophenotype and the clinico-haematological features.
abstract: Sixty-two previously untreated patients with B-cell chronic lymphocytic leukaemia were analysed to study the prognostic value of both the immunologic phenotype and the clinicobiologic characteristics. Univariate studies showed that none of the immunological markers analysed, sheep-rosette, mouse-rosette, slg, and HLA/DR, CD20, FMC7, CD5, and CD9 antigens, had a significant influence on survival. On the other hand, several clinical and haematological characteristics were identified as being associated with survival: 1) clinical features--presence of lymphadenopathies (P less than .05) and hepatomegaly and/or splenomegaly (P less than .04); 2) haematologic parameters--presence of anaemia and/or thrombopenia (P less than .05), the absolute peripheral blood lymphocyte count (P less than .03), and the presence of hypogammaglobulinemia (P less than .08); 3) biochemical parameters--serum uric acid (P less than .03); and 4) bone marrow histopathological features--biopsy pattern (P less than .04) and the percentage of lymphocytes in bone marrow aspirate (P less than .03). Both the Rai staging and the International Workshop on CLL staging systems were effective in identifying groups of patients with significantly different prognoses (P less than .05). Multivariate regression analysis demonstrated that the combination of three clinicopathologic characteristics (bone marrow histopathologic pattern, absolute peripheral blood lymphocyte count, and the presence or not of hypogammaglobulinaemia) had the strongest predictive relationship with survival time. In summary, our findings show that the clinicobiological and anatomopathologic parameters have much more prognostic relevance than the immunological markers analysed in the present study.
authors.affiliation: Servicio de Hematologia at Hospital Universitario, Salamanca, Spain.
authors.forename: A
authors.initials: A
authors.lastname: Orfao
authors.forename: M
authors.initials: M
authors.lastname: Gonzalez
authors.forename: J F
authors.initials: JF
authors.lastname: San Miguel
authors.forename: A
authors.initials: A
authors.lastname: Rios
authors.forename: M C
authors.initials: MC
authors.lastname: Canizo
authors.forename: J
authors.initials: J
authors.lastname: Hernandez
authors.forename: M L
authors.initials: ML
authors.lastname: Maricato
authors.forename: A
authors.initials: A
authors.lastname: Lopez Borrasca
mesh_terms: D000943:Antigens, Differentiation / Q000032:analysis; D000951:Antigens, Neoplasm / Q000032:analysis; D005260:Female; D006402:Hematologic Diseases / Q000150:complications; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications / Q000276:immunology* / Q000401:mortality; D008206:Lymphatic Diseases / Q000150:complications; D008297:Male; D010641:Phenotype; D011379:Prognosis; D013997:Time Factors
chemical_list: D000943:Antigens, Differentiation; D000951:Antigens, Neoplasm